Filing Details
- Accession Number:
- 0001209191-11-060164
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-12-07 20:29:10
- Reporting Period:
- 2011-12-05
- Filing Date:
- 2011-12-07
- Accepted Time:
- 2011-12-07 20:29:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1312622 | I Kaye Foster-Cheek | C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080 | Svp, Global Human Resources | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-12-05 | 26,500 | $26.38 | 57,414 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-12-05 | 29,500 | $43.56 | 27,914 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2011-12-05 | 26,500 | $0.00 | 26,500 | $26.38 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 64,500 | 2020-09-30 | No | 4 | M | Direct |
Footnotes
- The shares were sold at prices between $43.50 and $43.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Twenty-Five percent of the shares subject to the option vested and became exercisable one year from the date of grant and the remainder vest and become exercisable at a rate of 1/48th per month thereafter.
Billionaire Hedge Funds
